Skip to main content
VCbacked
Log inGet Started

Tribune Therapeutics

Stockholm, Sweden

Tribune Therapeutics specializes in building promising pipeline of novel medicines to treat patients with a wide range of fibrotic diseases.

$24.8M raised
Mar 2025
Series A
BiotechnologyPharmaceuticalTherapeutics

Top Investors

Novo HoldingsHealthCapInnovestorLifeArc VenturesIndustrifonden

Founder Contacts

19,000+ verified contacts
Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about Tribune Therapeutics

How much funding has Tribune Therapeutics raised?
Tribune Therapeutics has raised $24.8M in total funding. The most recent round was Series A. The last funding was announced in March 2025.
Who are Tribune Therapeutics's investors?
Tribune Therapeutics's investors include Novo Holdings, HealthCap, Innovestor, LifeArc Ventures, Industrifonden.
Where is Tribune Therapeutics headquartered?
Tribune Therapeutics is headquartered in Stockholm, Sweden.
What does Tribune Therapeutics do?
Tribune Therapeutics specializes in building promising pipeline of novel medicines to treat patients with a wide range of fibrotic diseases.
What stage is Tribune Therapeutics at?
Tribune Therapeutics is at the Series A stage.
Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .

MLA
"Tribune Therapeutics — Funding & Investors." VCBacked, March 26, 2025, https://www.vcbacked.co/company/tribune-therapeutics. Accessed June 4, 2026.
APA
VCBacked. (2025). Tribune Therapeutics — Funding & Investors. Retrieved June 4, 2026, from https://www.vcbacked.co/company/tribune-therapeutics
Wikipedia (cite web)
{{cite web |title=Tribune Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/tribune-therapeutics |website=VCBacked |access-date=June 4, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated .

Similar Companies in Biotechnology

View all
Virtuoso Surgical
Nashville
Pharvaris
Zug
Odyssey Therapeutics
Boston$213.0M
Tempus
Chicago
Anagram Therapeutics
Boston
Prenetics
Hong Kong